Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jul;66(1):171–176. doi: 10.1038/bjc.1992.237

Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value.

P K Lipponen 1, M J Eskelinen 1
PMCID: PMC1977906  PMID: 1353364

Abstract

Cell proliferation of transitional cell bladder cancer (TCC) was determined by PCNA (proliferating cell nuclear antigen)/cyclin immunostaining in 178 TCCs and the results were related to established prognostic factors, progression and survival during a mean follow-up period of 10 years. The fraction of PCNA/cyclin positive nuclei was related to T-category (P = 0.008), papillary status, WHO grade, DNA ploidy, S phase fraction, M/V index (volume corrected mitotic index) and AgNORs (silver stained nucleolar organiser regions) (for all P less than 0.001). TCCs presenting with pelvic lymph node metastasis at diagnosis had a significantly higher growth fraction than the tumours confined to the bladder wall (P less than 0.001). The fraction of PCNA/cyclin positive nuclei predicted progression in T-, N- and M-categories (P less than 0.001). In Ta-T1 tumours high fraction of PCNA/cyclin positive nuclei predicted metastasis (P = 0.019). In survival analysis the fraction of PCNA/cyclin positive nuclei predicted survival in the entire cohort (P less than 0.001) and in Ta-T1 tumours (P = 0.0005). In a multivariate survival analysis the fraction of PCNA/cyclin positive nuclei showed independent predictive value in the entire cohort (P = 0.046), in papillary tumours (P = 0.006) and in Ta-T1 tumours (P = 0.015). The results show that the growth fraction as determined by PCNA/cyclin immunostaining is a significant prognostic variable in TCC.

Full text

PDF
171

Images in this article

173Figure 1
on p.173

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almendral J. M., Huebsch D., Blundell P. A., Macdonald-Bravo H., Bravo R. Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins. Proc Natl Acad Sci U S A. 1987 Mar;84(6):1575–1579. doi: 10.1073/pnas.84.6.1575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Benjamin D. R., Gown A. M. Aberrant cytoplasmic expression of proliferating cell nuclear antigen in Hodgkin's disease. Am J Surg Pathol. 1991 Aug;15(8):764–768. doi: 10.1097/00000478-199108000-00006. [DOI] [PubMed] [Google Scholar]
  3. Berger M. S., Greenfield C., Gullick W. J., Haley J., Downward J., Neal D. E., Harris A. L., Waterfield M. D. Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer. 1987 Nov;56(5):533–537. doi: 10.1038/bjc.1987.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blomjous C. E., Schipper N. W., Vos W., Baak J. P., de Voogt H. J., Meijer C. J. Comparison of quantitative and classic prognosticators in urinary bladder carcinoma. A multivariate analysis of DNA flow cytometric, nuclear morphometric and clinicopathological features. Virchows Arch A Pathol Anat Histopathol. 1989;415(5):421–428. doi: 10.1007/BF00747743. [DOI] [PubMed] [Google Scholar]
  5. Bravo R., Frank R., Blundell P. A., Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987 Apr 2;326(6112):515–517. doi: 10.1038/326515a0. [DOI] [PubMed] [Google Scholar]
  6. Bush C., Price P., Norton J., Parkins C. S., Bailey M. J., Boyd J., Jones C. R., A'Hern R. P., Horwich A. Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Br J Cancer. 1991 Aug;64(2):357–360. doi: 10.1038/bjc.1991.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carbin B. E., Ekman P., Gustafson H., Christensen N. J., Silfverswärd C., Sandstedt B. Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. II. Prognostic importance. J Urol. 1991 May;145(5):972–976. doi: 10.1016/s0022-5347(17)38503-8. [DOI] [PubMed] [Google Scholar]
  8. Celis J. E., Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A. 1985 May;82(10):3262–3266. doi: 10.1073/pnas.82.10.3262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Collan Y., Torkkeli T., Kosma V. M., Pesonen E., Kosunen O., Jantunen E., Mariuzzi G. M., Montironi R., Marinelli F., Collina G. Sampling in diagnostic morphometry: the influence of variation sources. Pathol Res Pract. 1987 Jun;182(3):401–406. doi: 10.1016/S0344-0338(87)80077-8. [DOI] [PubMed] [Google Scholar]
  10. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13–20. doi: 10.1002/ijc.2910310104. [DOI] [PubMed] [Google Scholar]
  11. Haapasalo H., Collan Y., Atkin N. B., Pesonen E., Seppä A. Prognosis of ovarian carcinomas: prediction by histoquantitative methods. Histopathology. 1989 Aug;15(2):167–178. doi: 10.1111/j.1365-2559.1989.tb03064.x. [DOI] [PubMed] [Google Scholar]
  12. Haneda H., Katabami M., Miyamoto H., Isobe H., Shimizu T., Ishiguro A., Moriuti T., Takasaki Y., Kawakami Y. The relationship of the proliferating cell nuclear antigen protein to cis-diamminedichloroplatinum (II) resistance of a murine leukemia cell line P388/CDDP. Oncology. 1991;48(3):234–238. doi: 10.1159/000226934. [DOI] [PubMed] [Google Scholar]
  13. Jaskulski D., deRiel J. K., Mercer W. E., Calabretta B., Baserga R. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science. 1988 Jun 10;240(4858):1544–1546. doi: 10.1126/science.2897717. [DOI] [PubMed] [Google Scholar]
  14. Kamel O. W., LeBrun D. P., Davis R. E., Berry G. J., Warnke R. A. Growth fraction estimation of malignant lymphomas in formalin-fixed paraffin-embedded tissue using anti-PCNA/Cyclin 19A2. Correlation with Ki-67 labeling. Am J Pathol. 1991 Jun;138(6):1471–1477. [PMC free article] [PubMed] [Google Scholar]
  15. Kosma V. M., Collan Y., Kulju T., Aalto M. L., Jantunen E., Karhunen J., Selkäinaho K. Quantitation of staining for amyloid in histological sections: sources of variation, correlation analysis, and interstain reproducibility. Appl Pathol. 1986;4(1-2):74–82. [PubMed] [Google Scholar]
  16. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  17. Lipponen P. K., Eskelinen M. J., Kiviranta J., Nordling S. Classic prognostic factors, flow cytometric data, nuclear morphometric variables and mitotic indexes as predictors in transitional cell bladder cancer. Anticancer Res. 1991 Mar-Apr;11(2):911–916. [PubMed] [Google Scholar]
  18. Lipponen P. K., Eskelinen M. J., Kiviranta J., Pesonen E. Prognosis of transitional cell bladder cancer: a multivariate prognostic score for improved prediction. J Urol. 1991 Dec;146(6):1535–1540. doi: 10.1016/s0022-5347(17)38159-4. [DOI] [PubMed] [Google Scholar]
  19. Lipponen P. K., Eskelinen M. J., Nordling S. Progression and survival in transitional cell bladder cancer: a comparison of established prognostic factors, S-phase fraction and DNA ploidy. Eur J Cancer. 1991;27(7):877–881. doi: 10.1016/0277-5379(91)90138-4. [DOI] [PubMed] [Google Scholar]
  20. Lipponen P. K., Eskelinen M. J., Sotarauta M. Prediction of superficial bladder cancer by histoquantitative methods. Eur J Cancer. 1990;26(10):1060–1063. doi: 10.1016/0277-5379(90)90052-u. [DOI] [PubMed] [Google Scholar]
  21. Lipponen P. K., Eskelinen M. J. Volume-corrected mitotic index and mitotic activity index in transitional cell bladder cancer. Eur Urol. 1990;18(4):258–262. doi: 10.1159/000463925. [DOI] [PubMed] [Google Scholar]
  22. Miyachi K., Fritzler M. J., Tan E. M. Autoantibody to a nuclear antigen in proliferating cells. J Immunol. 1978 Dec;121(6):2228–2234. [PubMed] [Google Scholar]
  23. Morris G. F., Mathews M. B. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem. 1989 Aug 15;264(23):13856–13864. [PubMed] [Google Scholar]
  24. Rosenkilde Olsen P., Wolf H., Schroeder T., Fischer A., Højgaard K. Urothelial atypia and survival rate of 500 unselected patients with primary transitional-cell tumour of the urinary bladder. Scand J Urol Nephrol. 1988;22(4):257–263. doi: 10.3109/00365598809180796. [DOI] [PubMed] [Google Scholar]
  25. Shaaban A. A., Tribukait B., el-Bedeiwy A. F., Ghoneim M. A. Prediction of lymph node metastases in bladder carcinoma with deoxyribonucleic acid flow cytometry. J Urol. 1990 Oct;144(4):884–887. doi: 10.1016/s0022-5347(17)39615-5. [DOI] [PubMed] [Google Scholar]
  26. Travali S., Ku D. H., Rizzo M. G., Ottavio L., Baserga R., Calabretta B. Structure of the human gene for the proliferating cell nuclear antigen. J Biol Chem. 1989 May 5;264(13):7466–7472. [PubMed] [Google Scholar]
  27. Tsujihashi H., Nakanishi A., Matsuda H., Uejima S., Kurita T. Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. J Urol. 1991 Apr;145(4):846–849. doi: 10.1016/s0022-5347(17)38475-6. [DOI] [PubMed] [Google Scholar]
  28. Woods A. L., Hall P. A., Shepherd N. A., Hanby A. M., Waseem N. H., Lane D. P., Levison D. A. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology. 1991 Jul;19(1):21–27. doi: 10.1111/j.1365-2559.1991.tb00890.x. [DOI] [PubMed] [Google Scholar]
  29. Yu C. C., Hall P. A., Fletcher C. D., Camplejohn R. S., Waseem N. H., Lane D. P., Levison D. A. Haemangiopericytomas: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA). Histopathology. 1991 Jul;19(1):29–33. doi: 10.1111/j.1365-2559.1991.tb00891.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES